TitleAssistant Professor
InstitutionMD Anderson
DepartmentEmergency Medicine
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Esmail A, Badheeb M, Alnahar B, Almiqlash B, Sakr Y, Khasawneh B, Al-Najjar E, Al-Rawi H, Abudayyeh A, Rayyan Y, Abdelrahim M. Cholangiocarcinoma: The Current Status of Surgical Options including Liver Transplantation. Cancers (Basel). 2024 May 21; 16(11). PMID: 38893067; PMCID: PMC11171350.
    2. Hanif IH, Abdelrahim S, Al Shaarani M, Lu H, Ahmad R, Goswami S, Abudayyeh A. Immune Checkpoint Therapy-Induced Lupus Nephritis. Kidney Int Rep. 2024 May; 9(5):1534-1537. PMID: 38707799; PMCID: PMC11068939.
    3. Shatila M, Eshaghi F, Thomas AR, Kuang AG, Shah JS, Zhao B, Naz S, Sun M, Fayle S, Jin J, Abudayyeh A, Sheshadri A, Palaskas NL, Franco-Vega MC, Gaeta MS, Thomas AS, Zhang HC, Wang Y. Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center. Cancers (Basel). 2024 Jan 15; 16(2). PMID: 38254858; PMCID: PMC10814014.
    4. Abdelrahim M, Esmail A, Abudayyeh A, Murakami N, Victor D, Kodali S, Cheah YL, Simon CJ, Noureddin M, Connor A, Saharia A, Moore LW, Heyne K, Kaseb AO, Gaber AO, Ghobrial RM. Transplant Oncology: An Emerging Discipline of Cancer Treatment. Cancers (Basel). 2023 Nov 09; 15(22). PMID: 38001597; PMCID: PMC10670243.
    5. Parvathareddy V, Selamet U, Sen AA, Mamlouk O, Song J, Page VD, Abdelrahim M, Diab A, Abdel-Wahab N, Abudayyeh A. Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response. Cancers (Basel). 2023 Oct 27; 15(21). PMID: 37958355; PMCID: PMC10649345.
    6. Abudayyeh A, Karam S. Editorial: Women in onconephrology: 2022. Front Nephrol. 2023; 3:1240195. PMID: 37675366; PMCID: PMC10479605.
    7. Qureshi S, Arani N, Parvathareddy V, Tchakarov A, Abdelrahim M, Suarez-Almazor M, Zhang J, Gibbons DL, Heymach J, Altan M, Abudayyeh A. Case Report: Immune checkpoint inhibitor-induced multiorgan vasculitis successfully treated with rituximab. Front Nephrol. 2023; 3:1168614. PMID: 37675380; PMCID: PMC10479603.
    8. Abboud K, Umoru G, Esmail A, Abudayyeh A, Murakami N, Al-Shamsi HO, Javle M, Saharia A, Connor AA, Kodali S, Ghobrial RM, Abdelrahim M. Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology. Cancers (Basel). 2023 Feb 23; 15(5). PMID: 36900226; PMCID: PMC10000896.
    9. Badheeb M, Abdelrahim A, Esmail A, Umoru G, Abboud K, Al-Najjar E, Rasheed G, Alkhulaifawi M, Abudayyeh A, Abdelrahim M. Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening. Curr Oncol. 2022 11 15; 29(11):8693-8719. PMID: 36421339; PMCID: PMC9689647.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    10. Abudayyeh A, Suo L, Lin H, Mamlouk O, Abdel-Wahab N, Tchakarov A. Pathologic Predictors of Response to Treatment of Immune Checkpoint Inhibitor-Induced Kidney Injury. Cancers (Basel). 2022 Oct 27; 14(21). PMID: 36358686; PMCID: PMC9656112.
      Citations: 1     
    11. Awiwi MO, Abudayyeh A, Abdel-Wahab N, Diab A, Gjoni M, Xu G, Vikram R, Elsayes K. Imaging features of immune checkpoint inhibitor-related nephritis with clinical correlation: a retrospective series of biopsy-proven cases. Eur Radiol. 2023 Mar; 33(3):2227-2238. PMID: 36255488; PMCID: PMC9957799.
      Citations:    Fields:    Translation:Humans
    12. Gupta S, Strohbehn IA, Wang Q, Hanna PE, Seethapathy R, Prosek JM, Herrmann SM, Abudayyeh A, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, de Seigneux S, Campedel L, Kitchlu A, Shin DS, Coppock G, Lumlertgul N, Garcia P, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Benesova K, Jhaveri KD, Cortazar FB, Weins A, Zuo Y, Mooradian MJ, Reynolds KL, Leaf DE, Sise ME, ICPi-AKI Consortium. Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer. Kidney Int. 2022 10; 102(4):930-935. PMID: 35964800; PMCID: PMC9523226.
    13. Abdelrahim M, Esmail A, Umoru G, Westhart K, Abudayyeh A, Saharia A, Ghobrial RM. Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report. Curr Oncol. 2022 06 15; 29(6):4267-4273. PMID: 35735450; PMCID: PMC9221586.
      Citations: 1     Fields:    Translation:Humans
    14. Kawashima S, Joachim K, Abdelrahim M, Abudayyeh A, Jhaveri KD, Murakami N. Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates. Korean J Transplant. 2022 Jun 30; 36(2):82-98. PMID: 35919193; PMCID: PMC9296977.
    15. Abdelrahim M, Esmail A, Xu J, Umoru G, Al-Rawi H, Saharia A, Abudayyeh A, Victor D, McMillan R, Kodali S, Ghobrial RM. Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience. Front Oncol. 2022; 12:908687. PMID: 35719974; PMCID: PMC9201492.
      Citations: 1     
    16. Abdelrahim M, Al-Rawi H, Esmail A, Xu J, Umoru G, Ibnshamsah F, Abudayyeh A, Victor D, Saharia A, McMillan R, Al Najjar E, Bugazia D, Al-Rawi M, Ghobrial RM. Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series. Curr Oncol. 2022 05 17; 29(5):3585-3594. PMID: 35621680; PMCID: PMC9139862.
      Citations: 2     Fields:    Translation:Humans
    17. Abdelrahim M, Esmail A, Saharia A, Abudayyeh A, Abdel-Wahab N, Diab A, Murakami N, Kaseb AO, Chang JC, Gaber AO, Ghobrial RM. Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View. Cancers (Basel). 2022 Mar 30; 14(7). PMID: 35406533; PMCID: PMC8997123.
      Citations: 5     
    18. Abudayyeh A, Wanchoo R. Kidney Disease Following Hematopoietic Stem Cell Transplantation. Adv Chronic Kidney Dis. 2022 03; 29(2):103-115.e1. PMID: 35817518.
      Citations:    Fields:    Translation:Humans
    19. Schreiber B, Abdelrahim M, Abudayyeh A, Murakami N. Emerging Concepts in Managing Malignancy in Kidney Transplant Patients. Semin Nephrol. 2022 01; 42(1):63-75. PMID: 35618396; PMCID: PMC9139423.
      Citations: 1     Fields:    Translation:Humans
    20. Abdelrahim M, Esmail A, Abudayyeh A, Murakami N, Saharia A, McMillan R, Victor D, Kodali S, Shetty A, Nolte Fong JV, Moore LW, Heyne K, Gaber AO, Ghobrial RM. Transplant Oncology: An Evolving Field in Cancer Care. Cancers (Basel). 2021 Sep 29; 13(19). PMID: 34638395; PMCID: PMC8508383.
      Citations: 11     
    21. Abdelrahim M, Mamlouk O, Lin H, Lin J, Page V, Abdel-Wahab N, Swan J, Selamet U, Yee C, Diab A, Suki W, Abudayyeh A. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis. Oncoimmunology. 2021 05 23; 10(1):1927313. PMID: 34104543; PMCID: PMC8158025.
      Citations: 1     Fields:    Translation:Humans
    22. Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol. 2021 08 20; 39(24):2710-2719. PMID: 33929874; PMCID: PMC10166368.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    23. Lin JS, Mamlouk O, Selamet U, Tchakarov A, Glass WF, Sheth RA, Layman RM, Dadu R, Abdelwahab N, Abdelrahim M, Diab A, Yee C, Abudayyeh A. Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. Oncoimmunology. 2021 02 02; 10(1):1877415. PMID: 33643693; PMCID: PMC7872057.
      Citations: 4     Fields:    Translation:Humans
    24. Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Rondon G, Whited L, Gruschkus S, Fa'ak F, Daher M, Knape C, Safa H, Shoukier M, Suarez-Almazor ME, Marcotulli M, Ludford K, Gulbis AM, Konopleva M, Ohanian M, Ravandi F, Garcia-Manero G, Oran B, Popat UR, Mehta R, Alousi AM, Daver N, Champlin R, Diab A, Al-Atrash G. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. J Immunother Cancer. 2021 02; 9(2). PMID: 33637601; PMCID: PMC7919586.
      Citations: 2     Fields:    Translation:Humans
    25. Abdelrahim M, Abudayyeh A. Renal Toxicity. Adv Exp Med Biol. 2021; 1342:389-397. PMID: 34972976.
      Citations:    Fields:    Translation:Humans
    26. Murakami N, Mulvaney P, Danesh M, Abudayyeh A, Diab A, Abdel-Wahab N, Abdelrahim M, Khairallah P, Shirazian S, Kukla A, Owoyemi IO, Alhamad T, Husami S, Menon M, Santeusanio A, Blosser CD, Zuniga SC, Soler MJ, Moreso F, Mithani Z, Ortiz-Melo D, Jaimes EA, Gutgarts V, Lum E, Danovitch GM, Cardarelli F, Drews RE, Bassil C, Swank JL, Westphal S, Mannon RB, Shirai K, Kitchlu A, Ong S, Machado SM, Mothi SS, Ott PA, Rahma O, Hodi FS, Sise ME, Gupta S, Leaf DE, Devoe CE, Wanchoo R, Nair VV, Schmults CD, Hanna GJ, Sprangers B, Riella LV, Jhaveri KD, Immune Checkpoint Inhibitors in Solid Organ Transplant Consortium. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. 2021 07; 100(1):196-205. PMID: 33359528; PMCID: PMC8222056.
      Citations: 17     Fields:    Translation:Humans
    27. Lin JS, Wang DY, Mamlouk O, Glass WF, Abdelrahim M, Yee C, Abudayyeh A. Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab. J Immunother Cancer. 2020 10; 8(2). PMID: 33020246; PMCID: PMC7537330.
      Citations: 7     Fields:    Translation:Humans
    28. Abudayyeh A, Lin H, Mamlouk O, Abdelrahim M, Saliba R, Rondon G, Martinez CS, Delgado R, Page V, Rajasekaran A, Sanders PW, Qazilbash M. Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma. Leuk Lymphoma. 2020 12; 61(13):3101-3111. PMID: 32723196; PMCID: PMC9074107.
      Citations:    Fields:    Translation:Humans
    29. Abudayyeh A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Martinez CS, Page VD, Tarrand JJ, Kontoyiannis DP, Marin D, Oran B, Olson A, Jones R, Popat U, Champlin RE, Chemaly RF, Shpall EJ, Rezvani K. Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients. Transpl Infect Dis. 2020 Oct; 22(5):e13395. PMID: 32602954.
      Citations:    Fields:    Translation:HumansCells
    30. Mamlouk O, Lin JS, Abdelrahim M, Tchakarov AS, Glass WF, Selamet U, Buni M, Abdel-Wahab N, Abudayyeh A. Checkpoint inhibitor-related renal vasculitis and use of rituximab. J Immunother Cancer. 2020 07; 8(2). PMID: 32718987; PMCID: PMC7380836.
      Citations: 10     Fields:    Translation:Humans
    31. Abudayyeh A, Song J, Abdelrahim M, Dahbour I, Page VD, Zhou S, Shen C, Zhao B, Pai RN, Amaram-Davila J, Manzano JG, George MC, Yennu S, Mandayam SA, Nates JL, Moss AH. Renal Replacement Therapy in Patients With Stage IV Cancer Admitted to the Intensive Care Unit With Acute Kidney Injury at a Comprehensive Cancer Center Was Not Associated With Survival. Am J Hosp Palliat Care. 2020 Sep; 37(9):707-715. PMID: 31986903; PMCID: PMC7363512.
      Citations: 2     Fields:    Translation:Humans
    32. Abdelrahim M, Abudayyeh A. Renal Toxicity. Adv Exp Med Biol. 2020; 1244:287-293. PMID: 32301023.
      Citations:    Fields:    Translation:Humans
    33. Abudayyeh A. Onconephrology: An Evolving Field. Methodist Debakey Cardiovasc J. 2019 Oct-Dec; 15(4):305-307. PMID: 31988693; PMCID: PMC6977557.
      Citations: 1     Fields:    Translation:Humans
    34. Abdel-Wahab N, Safa H, Abudayyeh A, Johnson DH, Trinh VA, Zobniw CM, Lin H, Wong MK, Abdelrahim M, Gaber AO, Suarez-Almazor ME, Diab A. Corrections to: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer. 2019 Jun 24; 7(1):158. PMID: 31234936; PMCID: PMC6589871.
      Citations: 1     Fields:    
    35. Strati P, Abdelrahim M, Selamet U, Page VD, Pierce SA, Verstovsek S, Abudayyeh A. Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. Ann Hematol. 2019 Jul; 98(7):1611-1616. PMID: 31093708.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    36. Abdel-Wahab N, Safa H, Abudayyeh A, Johnson DH, Trinh VA, Zobniw CM, Lin H, Wong MK, Abdelrahim M, Gaber AO, Suarez-Almazor ME, Diab A. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer. 2019 04 16; 7(1):106. PMID: 30992053; PMCID: PMC6469201.
      Citations: 64     Fields:    Translation:Humans
    37. Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, Gaber L, Lahoti A, Workeneh B, Chen S, Lin J, Abdel-Wahab N, Tayar J, Lu H, Suarez-Almazor M, Tannir N, Yee C, Diab A, Abudayyeh A. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer. 2019 01 06; 7(1):2. PMID: 30612580; PMCID: PMC6322290.
      Citations: 82     Fields:    Translation:Humans
    38. Strati P, Glass WF, Abdelrahim M, Selamet U, Tchakarov A, Workeneh BT, Verstovsek S, Abudayyeh A. Renal complications of primary myelofibrosis. Leuk Lymphoma. 2019 02; 60(2):507-510. PMID: 29966471.
      Citations: 2     Fields:    Translation:Humans
    39. Abudayyeh A, Hamdi A, Abdelrahim M, Lin H, Page VD, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Oran B, Chemaly RF, Ahmed S, Abudayyeh I, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Rezvani K. Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. Transpl Infect Dis. 2017 Feb; 19(1). PMID: 27862740.
      Citations: 4     Fields:    Translation:HumansCells
    40. Ertem FU, Zhang W, Chang K, Mohaiza Dashwood W, Rajendran P, Sun D, Abudayyeh A, Vilar E, Abdelrahim M, Dashwood RH. Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc adenomas are downregulated in response to tumor suppression by Clotam. Int J Cancer. 2017 Jan 15; 140(2):460-468. PMID: 27706811.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    41. Cohen EP, Shirali A, Abudayyeh A, American Society of Nephrology Onco-Nephrology Forum, Finkel KW. Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy. Clin J Am Soc Nephrol. 2016 12 07; 11(12):2273-2279. PMID: 27526708; PMCID: PMC5142056.
      Citations: 12     Fields:    Translation:Humans
    42. Rajasekaran A, Ngo TT, Abdelrahim M, Glass W, Podoll A, Verstovsek S, Abudayyeh A. Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib. BMC Nephrol. 2015 Aug 01; 16:121. PMID: 26232031; PMCID: PMC4521341.
      Citations: 4     Fields:    Translation:Humans
    43. Hedrick E, Lee SO, Kim G, Abdelrahim M, Jin UH, Safe S, Abudayyeh A. Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma. PLoS One. 2015; 10(6):e0128308. PMID: 26035713; PMCID: PMC4452731.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    44. Abudayyeh A, Truong LD, Beck LH, Weber DM, Rezvani K, Abdelrahim M. Membranous nephropathy in autologous hematopoietic stem cell transplant: autologous graft-versus-host disease or autoimmunity induction? Clin Kidney J. 2015 Aug; 8(4):440-4. PMID: 26251713; PMCID: PMC4515891.
      Citations: 5     
    45. Safe S, Jin UH, Morpurgo B, Abudayyeh A, Singh M, Tjalkens RB. Nuclear receptor 4A (NR4A) family - orphans no more. J Steroid Biochem Mol Biol. 2016 Mar; 157:48-60. PMID: 25917081; PMCID: PMC4618773.
      Citations: 76     Fields:    Translation:Humans
    46. Nair V, Sreevalsan S, Basha R, Abdelrahim M, Abudayyeh A, Rodrigues Hoffman A, Safe S. Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors. J Biol Chem. 2014 Oct 03; 289(40):27692-701. PMID: 25143389; PMCID: PMC4183806.
      Citations: 67     Fields:    Translation:HumansAnimalsCells
    47. Abudayyeh AA, Lahoti A, Salahudeen AK. Onconephrology: the need and the emergence of a subspecialty in nephrology. Kidney Int. 2014 May; 85(5):1002-4. PMID: 24786870.
      Citations: 5     Fields:    Translation:Humans
    48. Maliakal P, Abdelrahim M, Sankpal UT, Maliakal C, Baker CH, Safe S, Herrera LJ, Abudayyeh A, Kaja S, Basha R. Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats. Invest New Drugs. 2012 Jun; 30(3):853-61. PMID: 21197621.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    49. Colon J, Basha MR, Madero-Visbal R, Konduri S, Baker CH, Herrera LJ, Safe S, Sheikh-Hamad D, Abudayyeh A, Alvarado B, Abdelrahim M. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs. 2011 Feb; 29(1):41-51. PMID: 19851711.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    50. Chintharlapalli S, Papineni S, Abdelrahim M, Abudayyeh A, Jutooru I, Chadalapaka G, Wu F, Mertens-Talcott S, Vanderlaag K, Cho SD, Smith R, Safe S. Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate in colon cancer cells. Int J Cancer. 2009 Oct 15; 125(8):1965-74. PMID: 19582879; PMCID: PMC2766353.
      Citations: 62     Fields:    Translation:HumansAnimalsCells
    51. Liu X, Abdelrahim M, Abudayyeh A, Lei P, Safe S. The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression. Mol Cancer Ther. 2009 May; 8(5):1207-17. PMID: 19435870; PMCID: PMC2939312.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    52. Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R, Abudayyeh A, Baker C, Herrera L, Safe S. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis. 2009 Jul; 30(7):1193-201. PMID: 19406933; PMCID: PMC2704282.
      Citations: 32     Fields:    Translation:HumansAnimalsCells
    53. Konduri S, Colon J, Baker CH, Safe S, Abbruzzese JL, Abudayyeh A, Basha MR, Abdelrahim M. Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther. 2009 Mar; 8(3):533-42. PMID: 19258429.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    54. Cho SD, Chintharlapalli S, Abdelrahim M, Papineni S, Liu S, Guo J, Lei P, Abudayyeh A, Safe S. 5,5'-Dibromo-bis(3'-indolyl)methane induces Kruppel-like factor 4 and p21 in colon cancer cells. Mol Cancer Ther. 2008 Jul; 7(7):2109-20. PMID: 18645021; PMCID: PMC2565496.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    55. Abdelrahim M, Safe S, Baker C, Abudayyeh A. RNAi and cancer: Implications and applications. J RNAi Gene Silencing. 2006 Feb 28; 2(1):136-45. PMID: 19771215; PMCID: PMC2737210.
      Citations: 11     
    56. Nuclear receptor 4A1 (NR4A1) as a drug target for renal cell adenocarcinoma. PLoS One. 10.
    57. Obstructive renal disease in cancer patients. 309-317.
    58. Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc adenomas are downregulated in response to tumor suppression by Clotam. International Journal of Cancer.
    59. Membranous nephropathy in autologous hematopoietic stem cell transplant. CKJ: Clinical Kidney Journal. 8:440-444.
    60. Current Strategies for Prevention and Management of Stem Cell Transplant-Related Urinary Tract and Voiding Dysfunction. Current Bladder Dysfunction Reports. 10:109-117.
    61. Fluid and Electrolyte Abnormalities in Patients with Cancer. 167-182.
    62. Nuclear receptor 4A (NR4A) family - Orphans no more. Journal of Steroid Biochemistry and Molecular Biology. 157:48-60.
    63. Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. Transplant Infectious Disease.
    64. Symptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients. American Journal of Transplantation.
    65. Primary myelofibrosis associated glomerulopathy. BMC Nephrology. 16.
    66. Disseminated cryptococcal infection in allogeneic stem cell transplant patients. Bone Marrow Transplantation. 51:1301-1304.
    ABUDAYYEH's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (204)
    Co-Authors (63)
    Similar People (60)
    Same Department Expand Description